ELISA Kit Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Product Type

ELISA Kit Market Overview

The ELISA (Enzyme-Linked Immunosorbent Assay) Kit market is poised for significant growth from 2025 to 2030, driven by advancements in biotechnology, increasing demand for diagnostic tools, and rising prevalence of chronic diseases. ELISA kits are widely used in research, diagnostics, and drug development due to their high sensitivity, specificity, and cost-effectiveness. The global ELISA Kit market is projected to grow at a CAGR of 5.8% during the forecast period, reaching a market size of approximately $2.5 billion by 2030.

Market Size and Share Analysis

The ELISA Kit market is segmented by product type, process, application, end-use, and region. In 2025, the market is estimated to be valued at $1.8 billion, with the Sandwich ELISA segment holding the largest market share of 45%-50%. The Competitive ELISA segment is expected to grow at a CAGR of 6.2%, driven by its increasing use in drug development and clinical diagnostics.

By Product Type

• Sandwich ELISA: Dominates the market with a share of 45%-50% in 2025, owing to its high sensitivity and specificity.
• Competitive ELISA: Expected to grow at a CAGR of 6.2%, driven by its application in drug development and clinical diagnostics.

By Key Players

The ELISA Kit market is highly competitive, with key players such as U-CyTech, Bethyl, BioLegend, Peprotech, MabTech, BioVision, and Rockland leading the market. These companies are focusing on product innovation, strategic partnerships, and mergers & acquisitions to strengthen their market position.

By Process

The market is segmented into manual and automated ELISA processes. The automated ELISA segment is expected to grow at a CAGR of 7.1%, driven by the increasing adoption of automation in laboratories to improve efficiency and reduce human error.

By Application

ELISA kits are widely used in various applications, including cancer research, infectious diseases, autoimmune diseases, and allergies. The infectious diseases segment holds the largest market share of 30%-35%, driven by the increasing prevalence of infectious diseases globally.

By End-Use

The market is segmented into hospitals, diagnostic laboratories, pharmaceutical & biotechnology companies, and academic & research institutes. The pharmaceutical & biotechnology companies segment is expected to grow at a CAGR of 6.5%, driven by increasing R&D activities in drug development.

By Region

North America dominates the ELISA Kit market with a share of 40%-45% in 2025, driven by the presence of key players, advanced healthcare infrastructure, and high R&D expenditure. The Asia-Pacific region is expected to grow at the highest CAGR of 8.2%, driven by increasing healthcare expenditure, rising prevalence of chronic diseases, and growing awareness about early disease diagnosis.

Market Trends

• Increasing Adoption of Automation: The adoption of automated ELISA processes is increasing, driven by the need for high-throughput screening and reduced human error.
• Rising Demand for Point-of-Care Testing: The demand for point-of-care testing is increasing, driven by the need for rapid and accurate diagnostic results.
• Growing Focus on Personalized Medicine: The growing focus on personalized medicine is driving the demand for ELISA kits in drug development and clinical diagnostics.

Market News on Policy and Companies

Recent developments in the ELISA Kit market include:

• Regulatory Approvals: Several ELISA kits have received regulatory approvals, driving market growth. For example, in 2025, BioLegend received FDA approval for its new ELISA kit for cancer biomarker detection.
• Strategic Partnerships: Key players are entering into strategic partnerships to expand their product portfolios and market reach. For example, in 2025, Peprotech partnered with a leading diagnostic company to develop new ELISA kits for infectious diseases.
• Mergers & Acquisitions: The market has witnessed several mergers and acquisitions, leading to market consolidation. For example, in 2025, MabTech acquired a smaller competitor to strengthen its market position.

Segment Forecasts (2025 - 2030)

The ELISA Kit market is expected to witness significant growth across all segments during the forecast period. Key forecasts include:

• Sandwich ELISA: Expected to grow at a CAGR of 5.8%, driven by its high sensitivity and specificity.
• Competitive ELISA: Expected to grow at a CAGR of 6.2%, driven by its application in drug development and clinical diagnostics.
• Automated ELISA: Expected to grow at a CAGR of 7.1%, driven by the increasing adoption of automation in laboratories.
• Pharmaceutical & Biotechnology Companies: Expected to grow at a CAGR of 6.5%, driven by increasing R&D activities in drug development.
• Asia-Pacific Region: Expected to grow at the highest CAGR of 8.2%, driven by increasing healthcare expenditure and rising prevalence of chronic diseases.

Conclusion

The ELISA Kit market is poised for significant growth from 2025 to 2030, driven by advancements in biotechnology, increasing demand for diagnostic tools, and rising prevalence of chronic diseases. The market is highly competitive, with key players focusing on product innovation, strategic partnerships, and mergers & acquisitions to strengthen their market position. The adoption of automated ELISA processes, rising demand for point-of-care testing, and growing focus on personalized medicine are key trends driving market growth. With a projected CAGR of 5.8%, the global ELISA Kit market is expected to reach a market size of approximately $2.5 billion by 2030.